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Abstract
Background: Antiretroviral therapy (ART) for HIV, taken daily, is an effective strategy to clinically suppress the virus,
providing the dual benefit of improved survival and vastly decreasing the risk of transmission. However, this highly
effective intervention has not yet reached all who could benefit. Cash transfers are increasingly recognized as an
effective strategy to motivate behavior change and improve HIV care and treatment outcomes, including engagement
in HIV care and adherence to ART. Despite a growing evidence base and strong theoretical foundation for the cash
transfer approach, key questions remain. To address these questions and begin to bridge the “know-do gap” with
respect to cash transfers, our team is employing an implementation science approach to iterative development of an
incentive-based intervention to promote ART uptake and adherence among people living with HIV (PLHIV) in the Lake
Zone region, Tanzania.
Methods: We will conduct a type I hybrid implementation–effectiveness trial to test the effectiveness of a
cash transfer intervention on the outcome of HIV viral suppression, and concurrently examine the potential
for real-world implementation with a mobile health technology (mHealth) system. Specifically, our team will
expand the intervention to 32 clinics and enroll 1984 PLHIV to (a) evaluate its effectiveness by conducting a
cluster randomized controlled trial with clinics as the unit of randomization and 12-month viral suppression as
the primary outcome and (b) evaluate the implementation challenges and successes at multiple levels
(patient, provider, clinic).
Discussion: This trial will provide evidence not only about the real-world effectiveness of cash transfers for
retention in HIV care and viral suppression, but also on the implementation challenges and successes that will
facilitate or hinder wider scale-up within Tanzania and beyond.
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Contributions to the literature
 Adherence to HIV antiretroviral therapy and
resulting viral suppression are widely known as
critical for ending the HIV epidemic.
 Effective implementation strategies to ensure that
people living with HIV have viral suppression are
needed; cash transfers are one such strategy.
 This study protocol describes a cluster randomized
controlled trial with an implementation–
effectiveness hybrid design to optimize a cash
transfer implementation strategy for HIV control in
real-world settings.
Background
Antiretroviral therapy (ART), taken every day as pre-
scribed, is an effective strategy to clinically suppress the
HIV virus, providing the dual benefit of improved health
and vastly decreasing or eliminating the risk of onward
transmission. Despite the robust evidence, this highly ef-
fective intervention has not yet reached all who could
benefit. For example, in Tanzania, 1.6 million people are
living with HIV, and 72,000 new infections occur yearly.
Of those living with HIV, only 62% are virally sup-
pressed, and of those who are currently on HIV treat-
ment and who have viral load testing results, 87% are
virally suppressed [1, 2]—falling short of the 95–95–95
goals that UNAIDS has set for 2030 for which 95% of
those on HIV treatment should be virally suppressed [2].
To reach these goals, new and effective strategies are
needed that can translate evidence into widespread prac-
tice and thereby bring sustained HIV treatment for viral
suppression to all people living with HIV (PLHIV).
Conditional economic incentives are increasingly rec-
ognized as one such implementation strategy: these pro-
grams typically provide cash (or other incentives) to
people who meet a particular condition, for example
testing for HIV, returning for HIV test results, or testing
negative for sexually transmitted infections, thus motiv-
ating certain behaviors that result in improved health.
Conditional economic incentive programs evaluated in
the context of improving HIV outcomes have largely
been short term and have primarily been implemented
in the context of research settings, differentiating them
from social protection cash transfer programs that are
typically longer term and funded by the government.
There is now a substantial evidence base demonstrating
the effectiveness of cash transfer programs in improving
outcomes along the HIV care continuum in low-
resource settings in a research context [3–23]. Despite
this strong evidence, few of these cash transfer programs
to improve HIV outcomes have been scaled, and gaps
exist in understanding the long-term impacts of these
programs.
To address these questions, we are employing an imple-
mentation science approach to evaluate a cash incentive
program designed to promote ART adherence among
PLHIV in the Lake Zone, Tanzania. Over the past several
years, our team has designed and conducted a set of itera-
tive experiments to determine the efficacy of the
incentive-based intervention, optimize the intervention for
a real-world clinical setting, and assess the feasibility and
acceptability of the intervention package for scale-up and
sustainability. The effectiveness trial described in this
protocol is the logical next step in evaluating incentive-
based approaches for improved HIV care outcomes. To-
gether, this set of trials (efficacy–optimization–effective-
ness) will generate an evidence base for the most effective,
incentive-based implementation strategy for the clinically
proven intervention of ART adherence.
Results from the first two randomized trials conducted
by our team (efficacy and optimization) demonstrated
that cash transfers conditional on visit attendance have
the potential to improve ART adherence and retention
in care among PLHIV in Tanzania. In the first study (ef-
ficacy), our team randomized 800 food-insecure PLHIV
who recently started ART at three clinics to the standard
of care or 6 months of cash or food transfers, conditional
on visit attendance [24]. After 6 months of the interven-
tion, we found that short-term cash transfers were su-
perior to the standard of care on all indicators of
adherence and retention, including the medication pos-
session ratio (MPR), a pharmacy-based measure of ad-
herence associated with viral suppression [25–28],
appointment attendance, and loss to follow-up [20]. At
12 months, 6 months after the intervention ended, the
cash group remained more likely to be in care than the
standard of care group and had superior appointment
attendance. Furthermore, cash transfers were safe to ad-
minister [29, 30] and, compared to food baskets, were
equal or superior to food support on all outcomes, were
cheaper and easier to monitor, and were preferred by
patients. Analysis of individual motivation found that
cash transfers do not undermine intrinsic motivation to
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adhere to HIV treatment; indeed, intrinsic motivation in-
creased over time as PLHIV experienced the benefits of
treatment [31]. Qualitative research revealed that money
received as part of the intervention was largely being
spent on food, school fees, and investment in assets and
small businesses.
Building on these proof-of-concept results, a second
trial (optimization) evaluated the cash transfer interven-
tion among 530 PLHIV initiating ART at four clinics.
This second study (completed in August 2019, Clinical-
Trials.gov: NCT03351556) evaluated two cash transfer
sizes (~ $5 and ~ $10) conditional on visit attendance
and, for the larger amount, confirmed the first trial’s re-
sults using viral suppression as the outcome at 6 months
(risk difference vs. control = 13.0 percentage points, 95%
CI 4.5–21.5) [19]. The study also assessed whether a
clinic-based mobile health technology (mHealth) system
could streamline intervention implementation; the sys-
tem was designed to identify patients biometrically
(using fingerprints) and to automatically transfer cash
via mobile money to eligible patients upon scanning in
for their visit [32].
Armed with evidence on the intervention’s efficacy
and an optimized implementation strategy using the lar-
ger cash amount and mHealth system, we will now con-
duct the third study, a type I hybrid implementation–
effectiveness trial [33]. This study will test the effective-
ness of the cash transfer intervention on the outcome of
viral suppression 6 months after the cash program ends
and concurrently examine the potential for real-world
implementation through measurement of implementa-
tion science constructs [33]. Specifically, our team will
expand the intervention to 32 clinics to (a) evaluate its
effectiveness by conducting a cluster randomized con-
trolled trial with clinics as the unit of randomization and
12-month viral suppression as the primary outcome—a
key indicator used in monitoring global progress towards
HIV epidemic control; and (b) evaluate the challenges
and successes by measuring implementation science out-
comes at multiple levels (patient, provider, clinic) follow-
ing Proctor’s framework and constructs [34]. This is the
next, logical stage of this research as we build the evi-
dence base for the eventual adoption of a streamlined
version of this intervention at scale.
Methods
Design
The study has two primary objectives:
1 Impact evaluation: Evaluate the effect of the 6-
month cash transfer program on viral suppression
(< 1000 copies/ml) at 12 months after starting ART.
The primary objective of this study is to evaluate
the effectiveness of the cash transfer program using
22,500 Tanzanian Shillings (TZS)/month (as
determined by phase I) at improving the proportion
of PLHIV retained on ART and with suppressed
viral load at 12 months after starting ART. Using a
cluster randomized control trial, with our sample
size of 32 clinics and 1984 participants (62
participants per clinic), we will have 80% power to
detect a risk difference (RD) of 11 percentage points
in viral suppression at 12 months between the
participants attending intervention and control
clinics.
The secondary outcomes of the impact evaluation
are:
 Viral suppression (< 1000 copies/ml) at 6
months;
 Retention on ART at 6 and 12 months;
 The proportion virally suppressed of those
retained on ART at 6 and 12 months; and
 Appointment attendance, the proportion of
scheduled visits that were completed during the
0–6- and 0–12-month periods.
2 Implementation study: Understand implementation
successes and challenges through measurement of
implementation outcomes, and use lessons learned
to inform wider adoption of cash transfer programs
for PLHIV.
Although evidence from our previous studies
demonstrates the preliminary effectiveness of cash
transfers on HIV-related outcomes, we do not yet
know the optimal strategy for implementing this
type of system at a larger scale and outside of a re-
search setting. Thus, in anticipation of the potential
adoption of the program by the Ministry of Health
or others, a primary objective of this study is to
gather information related to successful implemen-
tation practices and challenges needing attention
before scaling.
To address these aims, we will conduct a type I hy-
brid implementation–effectiveness study using a two-
arm, cluster randomized controlled trial (objective #1,
“impact evaluation”) with the health facility as the
unit of randomization (see Fig. 1). To measure imple-
mentation outcomes (objective #2, “implementation
study”) following Proctor’s framework [34], quantita-
tive and qualitative interviews will be conducted with
clinic staff (pharmacy staff, registration staff,
clinicians), clinic management, and patients at partici-
pating sites. Results will be used to assess heterogen-
eity in implementation practices and thus inform
optimization for potential scale-up. The study will be
conducted at 32 HIV primary care clinics in the fol-
lowing Lake Zone regions in Tanzania: Shinyanga,
Mwanza, Kagera, and Geita.
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Theoretical framework
The use of incentives for ART treatment adherence is
supported by several theories, including Self-
Determination Theory, which describes engagement in an
activity because of an external reward like a cash transfer
[35]. In addition, microeconomic theory posits that people
acquire more of a less costly good and less of a more ex-
pensive one [36] and that individuals often have high dis-
count rates or “present-biased preferences,” placing
disproportionate weight on the present while largely ig-
noring the future [37, 38]. An implication is that when a
behavior, like attending an HIV care visit, has small imme-
diate costs and large delayed benefits, a small immediate
incentive may counteract the present costs and tip the bal-
ance towards the positive behavior [7, 37]. The use of in-
centives for behavior change is also supported by
behavioral economic theory, which incorporates con-
structs from psychology to account for the predicable ir-
rationalities, heuristics, and biases of human behavior [39].
For example, “nudges” or short-term, small incentives can
change behavior [40, 41] and create new habits [42]—a
goal of the short-term cash transfer intervention.
The implementation science portion of the hybrid trial
is guided largely by Proctor’s implementation science
framework, which explores implementation successes
and challenges at multiple levels, including the patient,
provider, and clinic [34]. The study design follows
closely the typology of hybrid designs outlined by
Curran et al. [33] (type I in our case), for which the pri-
mary question is related to whether the intervention will
work in real-world clinical settings and the secondary
question relates to the potential barriers and facilitators
of widespread adoption of the intervention (Proctor’s
framework).
Clinic recruitment
We will engage Regional Medical Officers (RMOs) in
Shinyanga, Geita, Mwanza, and Kagera Regions,
Tanzania, to create a sampling frame of eligible study fa-
cilities within each region. Initial eligibility criteria for
clinics are as follows:
 Currently use an electronic medical record database;
 Average of at least 65 new ART initiates per quarter
in 2019, with no fewer than 35 ART initiates in any
single quarter in 2019;
 Within 100 km driving distance of a city center
(either Bukoba, Mwanza, Geita, Kahama, or
Shinyanga cities); and
 A minimum of 15 km from another study clinic.
The team will approach and enroll eligible selected
sites in a randomly assigned order (1 to 10 within each
region) until the target enrollment is reached, with the
goal of having 32 sites enroll in the study.
Fig. 1 Cluster randomized hybrid effectiveness–implementation trial study design
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Study arms
Control arm
Participants in the control arm will receive the standard
of care for PLHIV per the National Guidelines in
Tanzania [43], as delivered by the participating health fa-
cilities. In addition to the standard of care, the mHealth
system developed and utilized in the previous
(optimization) trial will be implemented in all study
clinics (intervention and control). This system was suc-
cessfully used in the clinics to enroll study participants,
track patient appointment attendance, and disburse cash
transfer payments for those eligible using automated
mobile money transfers [32]. We will adapt this mHealth
system for the current study and implement it in all
study facilities (intervention and control) for enrolling
participants, tracking participant visits, sending appoint-
ment reminders, and sending cash transfers via mobile
banking (cash transfer group only; consistent with pro-
cedures used in our previous studies). This strategy is
consistent with the Ministry of Health goal of using
mHealth strategies for patient care management in
Tanzania, as incorporated into the National Strategy for
HIV Care [44].
Intervention arm
In addition to the mHealth system as described above,
participants in the intervention arm will have the oppor-
tunity to receive up to 6 consecutive monthly cash trans-
fers of 22,500 TSH (~ $10) each, conditional on visit
attendance with the HIV care provider. Cash transfers
will be given once monthly for up to 6 months, spaced ≥
25 days apart (consistent with National Guidelines for
monthly or bimonthly visits [43]). This means that the
cash transfer is only given when the patient visits the
clinic for their routine appointment, regardless of
whether the visit is earlier or later than the scheduled
appointment (but no earlier than 25 days since the last
transfer). Upon the monthly visits when a patient checks
in for their appointment (via fingerprint or entry of
clinic ID), the cash transfer will be automatically distrib-
uted through the mHealth system. Transfer amounts are
exclusive of transaction fees (< $1), which will also be in-
cluded in the transfer. Thus, the intended amount is
transferred to the patient upon withdrawal.
If a participant does not have a mobile money account,
(1) s/he can sign up and return to the clinic on a differ-
ent day to link this account to the mHealth system or
(2) s/he may ask a trusted friend or relative to receive
the transfer. Mobile money is a secure and convenient
way for financial transactions, as mobile money kiosks
are ubiquitous in the study regions and mobile phone
ownership in Tanzania is high and approaching levels in
the USA (75% in 2018 and rapidly increasing [45]). For
participants who do not have mobile banking, wherever
possible, we will make referrals to kiosks where they can
sign up for the service, if desired. In the most recent
study, we found that 88% of participants had access to a
mobile phone and 79% had access to mobile banking.
Rationale for the cash amount and duration
Our now-completed study to optimize the intervention
found that both cash transfer amounts (10,000 TSH and
22,500 TSH per month) significantly improved 6-month
viral suppression versus the standard of care. At 6
months, we found a positive trend between incentive
size and HIV viral suppression (OR = 1.10 per 2500 TZS,
95% CI 1.03 to 1.17). Further, we found that both cash
amounts significantly improved HIV viral suppression
over the comparison group [10,000 TSH 83% vs. 73%,
risk difference (RD) = 10.2, 95% CI 1.6–18.8; 22,500 TSH
85% vs. 73%, RD = 12.1, 95% CI 3.6–20.6]; there was no
significant difference between incentive groups (RD =
1.9, 95% CI − 5.8 to 9.7). However, only the larger cash
value yielded significant improvements over the standard
of care for the secondary outcomes of retention in care
(RD = 7.1, 95% CI 0.3 to 13.9) and viral suppression
among the subset retained in care (RD = 7.8, 95% CI 0.9
to 14.7). To determine the final cash transfer size for the
current study, we followed our pre-registered analysis
plan (at AsPredicted), as well as several additional ana-
lyses including a cost analysis; discussions with local
stakeholders, including the Regional Medical Officers,
and co-investigators; assessment of budgetary trade-offs
associated with a smaller cash transfer versus larger
study size; and consideration about the benefits and
weaknesses of various cash amounts (including power
considerations and the ethics of engaging in a statisti-
cally underpowered study; for example, powering the
study for the smaller amount would require twice as
many clinics in the study, or the study would be signifi-
cantly underpowered). In addition, with expansion to
additional regions, some with higher average levels of so-
cioeconomic status than the region included in the
optimization trial, there was some concern that the
smaller transfer would be of lower value and thus not
enough to improve adherence. Finally, the larger cash
amount is of comparable magnitude to the monthly pay-
ments distributed through Tanzania’s social action fund,
TASAF. After considering these factors, many of which
are context-specific, we determined that the effectiveness
evaluation will include a cash transfer amount of 22,500
TSH per month for 6 months.
The intervention is intended to fit within the differen-
tiated model of care in Tanzania, in which patients start-
ing ART are scheduled monthly clinic visits until the
first viral load test at 6 months after ART initiation. At
that time, “stable” patients (those who have attained viral
suppression) are given 2-/3-month refill appointments
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and/or the opportunity to send a substitute for ART re-
fills or to obtain refills at community-based locations.
However, at 6 months, unstable patients (those without
viral suppression) continue monthly visits, with en-
hanced adherence interventions or change of regimen,
depending on clinical, immunological, and virological
criteria, until they are determined to have stabilized.
Note that we will track participation in enhanced adher-
ence counseling among participants in both arms and
present this in our results. Thus, the intervention is
intended to support patients during the vulnerable first
6 months of treatment before the 6-month decision
point for access to a less intensive clinic schedule.
Randomization and masking
Once facilities are selected for the study and have agreed
to participate, we will randomize 32 facilities to either
the SOC or the cash transfer intervention group at UC
Berkeley using the cvcrand package (cvrall command) in
R statistical software [46]. To ensure that the arms are
balanced on important covariates, and to mitigate the
possibility of ineffective randomization due to the small
numbers of clinics in the study, we will use a con-
strained randomization process [47]. This process essen-
tially pre-determines a set of acceptable allocations into
intervention and control clusters based on covariates of
relevance and then randomly selects an allocation from
the list of acceptable allocations [47]. Specifically, based
on our experience in phase 1, we will include the follow-
ing covariates in the constrained randomization process:
geographic region (Geita, Kagera, Mwanza, or Shi-
nyanga), facility level (hospital, health center, or dispens-
ary), driving distance to a major city (km), proximity to
a major road (< 5 km), and average number of ART initi-
ates per quarter. We will stratify on geographic region.
The 32 sites will be randomized 100,000 times, and we
will select the unique schemes as the randomization
space. Those iterations with an l2 balance score less than
the q = 0.1 cutoff will be retained. Among those
remaining iterations where there was little to no imbal-
ance detected, we will check for validity of the con-
strained randomization (e.g., no deterministic allocation
of clusters into arms) and ensure that there are sufficient
constrained randomizations from which to randomly se-
lect a single randomization scheme.
Facility staff will not be blinded to intervention assign-
ment. However, other clinic staff will not be informed
that there are intervention and control clinics in the
study, and clinical staff trainings for intervention clinics
and control clinics will be conducted separately. In
addition, participants will not be told during the consent
process that as part of the study there are intervention
and control clinics. The rationale for this is to prevent
behavioral changes such as patients transferring from
control to intervention clinics if they find out that there
are some clinics offering cash transfers to new ART cli-
ents. Although this is not expected to be a significant
problem based on feedback from local and regional
health authorities, given the small incentive value and
that participating facilities will be at least 15 km apart,
large numbers of transferring patients could compromise
the integrity of the study and will create an undue bur-
den for facility staff at intervention clinics.
Recruitment of participants
Impact evaluation
Recruitment of individuals for participation in the im-
pact portion of the study will take place within the en-
rolled clinics. All patients at study clinics who meet the
following inclusion criteria will be offered the opportun-
ity to participate in the study:
 Greater than or equal to 18 years of age
 Living with HIV infection
 Initiated on ART (for the first time) less than or
equal to 30 days prior to enrollment in the study
 Have access to a mobile phone (ownership, shared
ownership, or access to a trusted person’s phone)
 Do not intend to transfer to a different facility for
HIV care within the next 12 months
Eligible PLHIV at both intervention and standard of
care sites will be automatically identified by the mHealth
system upon registration in the system at a routine visit.
An automatic prompt will direct clinic registration staff
(who will manage the process) to the appropriate con-
sents and forms in the mHealth system, including per-
mission to access patient data as part of the study. If the
patient consents, s/he will automatically be assigned a
study ID. The study will use non-competitive enrollment
so that we can achieve approximately equal numbers of
study participants per site, with a goal of 62 per site.
Sites that reach this goal early will discontinue
enrollment.
Implementation study
Recruitment for participation in the implementation
science portion of the study for clinic staff will take
place in the intervention clinics once all participants
have reached their 6-month post-ART timepoint and
the cash transfer period (of 6 months) has ended. We
will purposefully select staff from all study clinics
such that our interviews include all levels of staff im-
pacted by the changes in the clinic as related to im-
plementation of the intervention (e.g., nurses,
registration staff, physicians, In-Charges, pharmacists).
Similarly, patients who have consented to and en-
rolled in the study will be purposefully sampled to
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assess their experiences with the cash transfer pro-
gram and the mHealth system after their completion
of cash transfer eligibility at 6 months. Specifically, we
will interview patients who (a) received all six cash
transfers, (b) received three or fewer of the six pos-
sible transfers, (c) enrolled in mobile money as a re-
sult of the study, (d) were virally suppressed at 6
months, and (e) were not virally suppressed at 6
months in addition to ensuring representation of both
men and women and a range of ages.
Outcomes and data collection
Primary outcome measure (impact evaluation, objective #1)
The primary endpoint is viral suppression at 12
months, defined as the proportion of PLHIV retained
in HIV primary care and with suppressed HIV viral
load 12 months after starting ART. The primary out-
come is expressed as a binary variable, defined as
PLHIV who are on ART and with sufficient HIV
viral suppression (< 1000 copies/ml, WHO’s thresh-
old for virologic failure in low- and middle-income
countries [48]) versus not on ART or viral failure (≥
1000 copies/ml). This outcome definition reflects
global “treatment as prevention” strategies including
the UNAIDS 95–95–95 targets, which aim for at
least 95% of PLHIV to be on ART and 95% of those
on ART virally suppressed. Patients considered not
on ART include those who died, stopped ART and/
or disengaged from care, or have not apparently re-
ceived ARVs for ≥ 28 days since their last missed
pharmacy pick-up [i.e., are lost to follow-up (LTFU)]
following PEPFAR Monitoring, Evaluation, and
Reporting Indicator Reference Guide Version 2.3 for
current ART [49].
Secondary outcome measures (impact evaluation, objective
#1)
 Viral suppression (< 1000 copies/ml) at 6 months;
 Retention on ART at 6 and 12months;
 The proportion virally suppressed of those retained
on ART at 6 and 12 months; and
 Appointment attendance, the proportion of
scheduled visits that were completed during the 0–
6- and 0–12-month periods.
Primary outcome measures (implementation study,
objective #2)
Implementation outcomes assessed through in-depth in-
terviews and surveys with patients and clinical staff:
adoption, acceptability, penetration, fidelity, feasibility,
appropriateness, and sustainability, plus usability
(Table 1).
Data collection
Data collection will include the following:
 Medical record review for the primary outcome,
viral suppression, at 6 and 12 months
 Surveys with patients at intervention and control
clinics at baseline and 6 and 12 months (n = 1984)
 In-depth interviews with patients in the intervention
clinics at 6 months (n = 30)
 Surveys with clinical staff at intervention and
control clinics at 6 months (n = 110)
 In-depth interviews with clinical staff at intervention
and control clinics at 6 months (n = 40)
We linked each data collection activity for the imple-
mentation study to implementation outcomes in the
Table 1 Implementation study: data collection approaches and Proctor’s implementation science constructs
Data collection approach Implementation
outcomes
Outcome indicators
Patient survey (baseline, 6 months) Adoption (mobile
money)
Initiation of use of mobile money; satisfaction with
the program generally and the mHealth system specifically
Acceptability




In-depth interviews with clinic staff (6
months)
Acceptability Staff support and acceptance, staff burden, practicality, and perceived fit
Appropriateness
Sustainability
In-depth interviews with patients plus
usability survey (6 months)
Acceptability Patient satisfaction with program and delivery model, impact on patient,
practicality and perceived fit, adoption of mobile money
Appropriateness
Adoption
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Proctor et al. framework (Table 1) [34]. We will analyze
data from structured surveys and in-depth interviews to
examine the implementation constructs of acceptability,
penetration, sustainability, appropriateness, adoption,
feasibility, and fidelity. We will use validated surveys to
assess the usability of the mHealth system from both the
clinic staff and patient perspectives, including the System
Usability Scale [50] and the Health Information Tech-
nology Usability Evaluation Scale [51].
Participant tracing—impact evaluation
As retention in care is included as part of the definition
of the primary outcome of this study (i.e., those not
retained on ART are included in the denominator of the
primary outcome of viral suppression), no additional re-
tention activities will be implemented other than the
routine procedures already in place and led by clinical
staff. According to national guidelines, patients who miss
a scheduled appointment are tracked in the community
by a system of home-based care providers (HBCs); this
system will remain in place during the study. In addition,
we will closely track implementation of patient tracking
as specified in the national guidelines within each study
clinic so that we can capture any variation in implemen-
tation at the clinic level. Research staff will not be in-
volved in tracing participants at any study facility during
the 12-month follow-up of each participant. At endline
only (12 months), research assistants will enhance these
procedures with additional robust tracing using “gold-
standard” tracing methods (at least 3 tracing attempts
using multiple methods), procedures to investigate all
potentially LTFU patients, confirm “silent transfers”
(those who transfer to new facilities without notification
of the prior facility) and deaths, and refer patients to
health facilities where missing plasma specimens can be




The sample size was determined for the impact study to
evaluate the effectiveness of the cash transfer program at
improving the proportion of PLHIV with suppressed viral
load (< 1000 copies/ml) at 12months. We used estimates
of viral suppression at 12months and ICC = 0.05, esti-
mated from a previous cluster randomized study of HIV
treatment adherence that we conducted among HIV-
infected pregnant women in Shinyanga Region, an ICC
consistent with previous studies [52]. Using site-adjusted
data about viral suppression at 6months from phase I
(75.2% in the control group), along with estimates of viral
suppression decline between 6 and 12months, we esti-
mate that viral suppression among adults at 12months in
the comparison sites will (conservatively) be 70%. With an
ICC of 0.05, 32 facilities, 80% power, and 56 PLHIV per
clinic (n = 1792), the minimum detectable effect is 11 per-
centage points as an absolute reduction in the proportion
experiencing viral suppression. In the second trial
(optimization), we achieved a 12.6 percentage point differ-
ence with the 22,500 TSH cash transfer at 6months, so
we believe this effect size is achievable. In addition, if viral
suppression is lower than expected in the comparison
arm, and the effect of the intervention remains stable,
power will increase. We will inflate the target sample size
by 10% to n = 1984 (62 participants per clinic across 32
clinics) to account for unexpected issues or significant dif-
ferences in the enrollment between clinics.
Data analysis—impact study
We will conduct an intent-to-treat analysis to determine
the effect of the intervention on 12-month viral suppres-
sion (the primary outcome). We will conduct a cluster-
based permutation test on the individual-level outcome
data, which accounts for clustering within the clinic.
The effect estimate of interest is the risk difference of
viral suppression among PLHIV attending intervention
versus comparison facilities. We will pre-register our
analysis plan at AsPredicted.
We will conduct several secondary analyses of the pri-
mary outcome, although we are not powered for these
analyses. We will examine heterogeneity in the primary
analysis by facility and patient characteristics. We will
also conduct a treatment-on-the-treated analysis to iso-
late the impact of incentive delivery [53–55].
Using the same methods as for the primary analysis,
we will also assess effects on the following key secondary
outcomes:
 Viral suppression (< 1000 copies/ml) at 6 months;
 Retention on ART at 6 and 12months;
 The proportion virally suppressed of those retained
on ART at 6 and 12 months; and
 Appointment attendance, the proportion of
scheduled visits that were completed during the 0–
6- and 0–12-month periods.
We will additionally assess effects on the following
survey-based outcomes at 6 and 12months:
 Food security




 Participation in the labor force/functional status
 Other indicators of household welfare (e.g.,
investment in small businesses)
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Data analysis—implementation study
Following each in-depth interview, the interviewer will
memo then debrief with the study team to discuss emer-
gent themes. Debriefings will be held weekly with inter-
viewers and the PI to ensure consistency and quality of
data collection. Audio-recordings from IDIs will be ver-
batim transcribed and translated into English. Data ana-
lysis will follow an open-coding approach [56, 57] and
will be based on research questions, study aims, and
Proctor’s implementation constructs. An initial coding
framework will include a list of predefined analytical
terms relating to Proctor’s constructs; however, data
analysis will be iterative, allowing new themes to emerge
throughout the analysis process [58]. Data will be coded
independently by two members of the research team
using Dedoose qualitative coding software. Concepts will
be grouped into categories, and main themes will be ex-
tracted and summarized in an analytic theme matrix.
Implementation outcome data from structured surveys
with clinical staff will be analyzed descriptively using
both STATA and Dedoose. We will synthesize quantita-
tive and qualitative data to produce a comprehensive set
of implementation outcome indicators. We will then use
the implementation indicators to assess variation in how
the program was implemented across the intervention
clinics, for example, exploring levels of penetration and
fidelity of the mHealth system, and explore variation in
effectiveness using a sensitivity analysis. Note that we
are not powered to show statistical differences in viral
suppression by variation in implementation outcomes.
Discussion
Achieving global goals for HIV epidemic control will ne-
cessitate new implementation strategies to identify
PLHIV, link them to high-quality HIV care and treat-
ment, and retain them on lifelong ART. Cash transfers
have emerged as a promising strategy worthy of consid-
eration as part of a comprehensive approach to HIV pre-
vention and care. We have used an iterative process
grounded in implementation science approaches to dem-
onstrate the efficacy of cash transfers for ART adherence
(trial 1) [20] and optimize the cash intervention with re-
spect to cash amount (trial 2) [19]. Now, in our third
trial, we will evaluate the effectiveness of cash transfers
on viral suppression with a contemporaneous assess-
ment of implementation outcomes with the goal of pre-
paring the intervention for scale in the complex context
of low- and middle-income country health systems. The
results from this type I hybrid implementation–effective-
ness trial will provide much-needed data on not only the
real-world effectiveness of cash transfers for ART adher-
ence and viral suppression, but also the implementation
challenges and successes that will facilitate or hinder
wider scale-up within Tanzania and beyond.
The hybrid implementation science/effectiveness ap-
proach will permit (a) a contribution to what is known
about the use of short-term cash transfers for PLHIV in
a real-world setting in sub-Saharan Africa, including
their long-term effects on viral suppression, and (b) an
understanding of how to optimize implementation ap-
proaches, and thus, provide guidance for policymakers
in facilitating successful scale-up. These results have the
potential to provide the evidence needed to show that
short-term assistance confers lasting benefits for those
starting treatment, providing needed support as they
begin to feel the beneficial effects of ART. Furthermore,
the study is based in the Lake Zone region of Tanzania,
a region that faces challenges common throughout sub-
Saharan Africa: a shortage of skilled personnel, poverty
and food insecurity, and pervasive challenges with reten-
tion in care. For these reasons, our results are likely to
have a high level of external validity and policy relevance
in sub-Saharan Africa.
We have intentionally designed the hybrid trial to be
largely self-sufficient—that is, clinical staff have the major-
ity of interaction with the research participants, with sup-
port from research staff initially, and then only as needed.
This approach comes with some trade-offs and limita-
tions. First, there is the strong possibility that implementa-
tion of the intervention may differ by site. While
implementation differences have the potential to dilute
the effect of the cash program, for an effectiveness trial in
a real-world setting, such variation will provide essential
knowledge that will allow best practices and lessons
learned to emerge and guide policymakers in bringing the
program to scale. Second, patients attending control
clinics may hear about the intervention and transfer out of
control clinics and into intervention clinics. To mitigate
this possibility (though this was not an issue in the first
two trials), we have included a minimum geographic dis-
tance between clinics to minimize spillover effects and
prevent contamination of comparison communities. In
addition, as large numbers of transferring patients would
compromise the integrity of the study and will create an
undue burden for facility staff at intervention clinics, we
will not reveal that there are intervention clinics where pa-
tients will receive cash transfers as part of the study to pa-
tients enrolling in the study at control clinics. Third, there
is substantial variability over time and across clinics in the
number of new ART initiates, and this variability may po-
tentially impact the rate at which we are able to enroll pa-
tients into the study.
The results of this hybrid implementation–effective-
ness trial will guide policymakers in Tanzania and else-
where in the Region about whether this intervention
should (or should not) be considered in national HIV/
AIDS programs, and if it should, how implementation
should proceed to optimize the effectiveness of the
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intervention in clinics across the country. Consequently,
this effectiveness trial has been designed with an eye to-
wards real-world, future scale-up, such that the proce-
dures we propose to follow align as closely as possible
with the National policy and consistent with what clinics
would and could do outside of a research study setting.
Trial status
Protocol version: 1.2
Recruitment start date: pending, recruitment sched-
uled to begin in November 2020
Anticipated recruitment completion date: May 2021
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